![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: LIPG |
Gene summary for LIPG |
![]() |
Gene information | Species | Human | Gene symbol | LIPG | Gene ID | 9388 |
Gene name | lipase G, endothelial type | |
Gene Alias | EDL | |
Cytomap | 18q21.1 | |
Gene Type | protein-coding | GO ID | GO:0006082 | UniProtAcc | B4DTR8 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
9388 | LIPG | HTA11_1391_2000001011 | Human | Colorectum | AD | 6.69e-06 | 6.66e-01 | -0.059 |
9388 | LIPG | HTA11_7663_2000001011 | Human | Colorectum | SER | 1.48e-04 | 7.39e-01 | 0.0131 |
9388 | LIPG | HTA11_7696_3000711011 | Human | Colorectum | AD | 1.63e-09 | 4.45e-01 | 0.0674 |
9388 | LIPG | HTA11_6818_2000001011 | Human | Colorectum | AD | 1.03e-02 | 4.72e-01 | 0.0112 |
9388 | LIPG | HTA11_6818_2000001021 | Human | Colorectum | AD | 4.64e-02 | 3.55e-01 | 0.0588 |
9388 | LIPG | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 6.11e-04 | 8.75e-01 | 0.3487 |
9388 | LIPG | HTA11_99999965104_69814 | Human | Colorectum | MSS | 5.29e-06 | 5.28e-01 | 0.281 |
9388 | LIPG | Adj_PTCwithHT_6 | Human | Thyroid | HT | 1.57e-08 | -5.85e-01 | 0.02 |
9388 | LIPG | Adj_PTCwithHT_8 | Human | Thyroid | HT | 4.82e-03 | -4.96e-01 | 0.0267 |
9388 | LIPG | PTCwithHT_6 | Human | Thyroid | HT | 5.45e-11 | -5.91e-01 | 0.02 |
9388 | LIPG | PTCwithHT_8 | Human | Thyroid | HT | 6.59e-08 | -5.61e-01 | 0.0351 |
9388 | LIPG | PTCwithoutHT_2 | Human | Thyroid | PTC | 1.16e-04 | -4.97e-01 | 0.0419 |
9388 | LIPG | male-WTA | Human | Thyroid | PTC | 6.71e-46 | 2.27e-01 | 0.1037 |
9388 | LIPG | PTC01 | Human | Thyroid | PTC | 1.63e-12 | -1.08e-01 | 0.1899 |
9388 | LIPG | PTC05 | Human | Thyroid | PTC | 3.30e-04 | -6.77e-02 | 0.2065 |
9388 | LIPG | PTC06 | Human | Thyroid | PTC | 1.47e-06 | 1.18e-01 | 0.2057 |
9388 | LIPG | PTC07 | Human | Thyroid | PTC | 2.36e-12 | 1.61e-01 | 0.2044 |
9388 | LIPG | ATC08 | Human | Thyroid | ATC | 3.87e-02 | -5.98e-01 | 0.0541 |
9388 | LIPG | ATC09 | Human | Thyroid | ATC | 4.12e-03 | -3.96e-01 | 0.2871 |
9388 | LIPG | ATC12 | Human | Thyroid | ATC | 2.20e-12 | -5.76e-01 | 0.34 |
Page: 1 2 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0031667 | Colorectum | AD | response to nutrient levels | 138/3918 | 474/18723 | 1.22e-05 | 2.68e-04 | 138 |
GO:0016042 | Colorectum | AD | lipid catabolic process | 97/3918 | 320/18723 | 4.31e-05 | 7.56e-04 | 97 |
GO:0006631 | Colorectum | AD | fatty acid metabolic process | 114/3918 | 390/18723 | 5.58e-05 | 9.44e-04 | 114 |
GO:0044242 | Colorectum | AD | cellular lipid catabolic process | 66/3918 | 214/18723 | 3.96e-04 | 4.50e-03 | 66 |
GO:0010876 | Colorectum | AD | lipid localization | 120/3918 | 448/18723 | 1.59e-03 | 1.33e-02 | 120 |
GO:0006869 | Colorectum | AD | lipid transport | 108/3918 | 398/18723 | 1.67e-03 | 1.39e-02 | 108 |
GO:0006644 | Colorectum | AD | phospholipid metabolic process | 101/3918 | 383/18723 | 5.80e-03 | 3.67e-02 | 101 |
GO:00160421 | Colorectum | SER | lipid catabolic process | 77/2897 | 320/18723 | 3.52e-05 | 9.18e-04 | 77 |
GO:00316671 | Colorectum | SER | response to nutrient levels | 106/2897 | 474/18723 | 3.94e-05 | 1.00e-03 | 106 |
GO:00442421 | Colorectum | SER | cellular lipid catabolic process | 51/2897 | 214/18723 | 8.60e-04 | 1.05e-02 | 51 |
GO:0046486 | Colorectum | SER | glycerolipid metabolic process | 82/2897 | 392/18723 | 2.26e-03 | 2.17e-02 | 82 |
GO:00066441 | Colorectum | SER | phospholipid metabolic process | 79/2897 | 383/18723 | 3.94e-03 | 3.24e-02 | 79 |
GO:00066311 | Colorectum | SER | fatty acid metabolic process | 79/2897 | 390/18723 | 6.34e-03 | 4.56e-02 | 79 |
GO:00316672 | Colorectum | MSS | response to nutrient levels | 125/3467 | 474/18723 | 1.24e-05 | 2.88e-04 | 125 |
GO:00066312 | Colorectum | MSS | fatty acid metabolic process | 95/3467 | 390/18723 | 2.20e-03 | 1.84e-02 | 95 |
GO:0046394 | Colorectum | MSS | carboxylic acid biosynthetic process | 76/3467 | 314/18723 | 6.71e-03 | 4.38e-02 | 76 |
GO:00108761 | Colorectum | MSS | lipid localization | 104/3467 | 448/18723 | 6.76e-03 | 4.38e-02 | 104 |
GO:00160422 | Colorectum | MSS | lipid catabolic process | 77/3467 | 320/18723 | 7.43e-03 | 4.71e-02 | 77 |
GO:0016053 | Colorectum | MSS | organic acid biosynthetic process | 76/3467 | 316/18723 | 7.88e-03 | 4.84e-02 | 76 |
GO:00463941 | Colorectum | MSI-H | carboxylic acid biosynthetic process | 36/1319 | 314/18723 | 2.68e-03 | 3.48e-02 | 36 |
Page: 1 2 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa005612 | Colorectum | MSS | Glycerolipid metabolism | 23/1875 | 63/8465 | 6.55e-03 | 2.64e-02 | 1.62e-02 | 23 |
hsa005613 | Colorectum | MSS | Glycerolipid metabolism | 23/1875 | 63/8465 | 6.55e-03 | 2.64e-02 | 1.62e-02 | 23 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
LIPG | SNV | Missense_Mutation | novel | c.499G>A | p.Gly167Ser | p.G167S | Q9Y5X9 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
LIPG | SNV | Missense_Mutation | c.959G>A | p.Gly320Asp | p.G320D | Q9Y5X9 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
LIPG | SNV | Missense_Mutation | novel | c.1004A>G | p.Tyr335Cys | p.Y335C | Q9Y5X9 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-AJ-A3OJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
LIPG | SNV | Missense_Mutation | c.620N>T | p.Arg207Met | p.R207M | Q9Y5X9 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
LIPG | SNV | Missense_Mutation | c.13N>A | p.Val5Ile | p.V5I | Q9Y5X9 | protein_coding | tolerated(0.21) | benign(0.005) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
LIPG | SNV | Missense_Mutation | novel | c.637N>A | p.Ala213Thr | p.A213T | Q9Y5X9 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
LIPG | SNV | Missense_Mutation | novel | c.965A>G | p.Asn322Ser | p.N322S | Q9Y5X9 | protein_coding | deleterious(0.04) | probably_damaging(0.999) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
LIPG | SNV | Missense_Mutation | novel | c.589N>T | p.Pro197Ser | p.P197S | Q9Y5X9 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
LIPG | SNV | Missense_Mutation | c.668C>T | p.Thr223Met | p.T223M | Q9Y5X9 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
LIPG | SNV | Missense_Mutation | rs111384586 | c.346G>A | p.Ala116Thr | p.A116T | Q9Y5X9 | protein_coding | deleterious(0.03) | probably_damaging(1) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
9388 | LIPG | DRUGGABLE GENOME, ENZYME, LIPASE, CELL SURFACE, PHOSPHOLIPASE | GSK-264220A | |||
9388 | LIPG | DRUGGABLE GENOME, ENZYME, LIPASE, CELL SURFACE, PHOSPHOLIPASE | inhibitor | 404859111 | ||
9388 | LIPG | DRUGGABLE GENOME, ENZYME, LIPASE, CELL SURFACE, PHOSPHOLIPASE | inhibitor | 178103308 |
Page: 1 |